Finance

Lists
CTNM:NASDAQ
Contineum Therapeutics Inc
9,67 USD
-1,93%
(-0,19) 1D
9,67 USD
0,00% (0,00)
After hours
Closed: 16-ноя., 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTNM...
Open
9,67 USD
High
9,93 USD
Low
9,46 USD
Mkt. cap
379,70 млн
Avg. vol.
1,03 млн
Volume
348,15 миң
52-wk high
17,78 USD
52-wk low
6,72 USD
EPS
-1,77 USD
Shares outstanding
35,35 млн
No. of employees
51
Open
9,67 USD
High
9,93 USD
Low
9,46 USD
Mkt. cap
379,70 млн
Avg. vol.
1,03 млн
Volume
348,15 миң
52-wk high
17,78 USD
52-wk low
6,72 USD
EPS
-1,77 USD
Shares outstanding
35,35 млн
No. of employees
51
News stories
From web sources and news partners
About Contineum Therapeutics Inc
CEO-
Employees51
Founded2009
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 8 analysts giving stock ratings to CTNM in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CTNM in the last 3 months.
Highest
Current 9,67 USD
30,00 USD (+210,24%)
Average
22,14 USD (+128,96%)
Lowest
14,00 USD (+44,78%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Abrahams
RBC Capital
Buy
Maintained
21,00 USD
+117,2%
11/03/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
30,00 USD
+210,2%
11/03/2026
Charles Moore
Robert W. Baird
Hold
Downgraded
14,00 USD
+44,8%
10/14/2026
Sean Laaman
Morgan Stanley
Hold
Maintained
17,00 USD
+75,8%
10/12/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
28,00 USD
+189,6%
10/12/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/30/2026
Gaurav Maini
LifeSci Capital
Buy
Maintained
23,00 USD
+137,8%
09/29/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
22,00 USD
+127,5%
09/16/2026
Last report
2026-ж., 3-ноя.
Fiscal period
Q3 2026
-0,49 USD / -0,45 USD
-8,20%miss
Revenue / Est. (USD)
- / 0,00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
12,00 млн
11,14 млн
11,97 млн
15,26 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,12 млн
5,76 млн
5,45 млн
5,70 млн
Operating expense
17,12 млн
16,90 млн
17,43 млн
20,97 млн
Total operating expenses
17,12 млн
16,90 млн
17,43 млн
20,97 млн
Operating income
-17,12 млн
-16,90 млн
-17,43 млн
-20,97 млн
Other non operating income
-51,00 миң
-57,00 миң
-68,00 миң
-93,00 миң
EBT including unusual items
-15,16 млн
-14,46 млн
-15,15 млн
-18,70 млн
EBT excluding unusual items
-15,16 млн
-14,46 млн
-15,15 млн
-18,70 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15,16 млн
-14,46 млн
-15,15 млн
-18,70 млн
Net profit margin
-
-
-
-
Earnings per share
-0,49
-0,39
-0,40
-0,49
Interest and investment income
2,01 млн
2,50 млн
2,34 млн
2,36 млн
Interest expense
-
-
-
-
Net interest expenses
2,01 млн
2,50 млн
2,34 млн
2,36 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-17,03 млн
-16,82 млн
-17,29 млн
-20,88 млн
Gain or loss from assets sale
-
2,00 миң
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору